Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The International Institute Of Cancer Immunology Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to multiple distinct examiners and 2 distinct art units. This indicates that the institute's oncology-related filings are being reviewed in different specialized divisions of the USPTO.
MARTINEZ, TARA L is the busiest examiner for the institute, holding 1 pending office action. Since there are multiple distinct examiners for the pending actions, the workload is split evenly between them. This distribution allows the institute to gain insights from different examiners within the biotechnology field.
The presence of 2 distinct art units for the pending actions requires the institute to monitor separate units for potential differences in examination trends. Each unit may have its own procedural nuances that could affect the prosecution of the pending matters. Tailoring the approach for each of the pending office actions will be important for navigating the complexities of the USPTO's review process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTINEZ, TARA L | 1 | 62.7% | +65.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682058 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING OR PREVENTING CANCER | MARTINEZ, TARA L | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682058 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING OR PREVENTING CANCER | MARTINEZ, TARA L | 1654 | §102§112DP | Non-Final OA | — | Pending | Feb 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInternational Institute Of Cancer Immunology Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Tara L Martinez has the most, with 1 of International Institute Of Cancer Immunology Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
